(Q46082611)

19 December 2017

title

Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice (English)

1 reference

19 December 2017

1 reference

1

Grazyna Biala

1 reference

19 December 2017

Marta Kruk-Slomka

series ordinal

2

object named as

Marta Kruk

1 reference

19 December 2017

language of work or name

1 reference

1 April 2009

1 reference

19 December 2017

Journal of Pharmacy and Pharmacology

published in

1 reference

19 December 2017

volume

61

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

493-502

1 reference

19 December 2017

Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Bupropion attenuates nicotine abstinence syndrome in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Development of tolerance to nicotine's anxiogenic effect in the social interaction test

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

The use of a plus-maze to measure anxiety in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Validation of a modified mirrored chamber sensitive to anxiolytics and anxiogenics in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Presynaptic nicotinic ACh receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

21 January 2018

Glutamate and anxiety

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Calcium channel antagonists suppress cross-tolerance to the anxiogenic effects of D-amphetamine and nicotine in the mouse elevated plus maze test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Adverse effects of stimulant drugs in a community sample of drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to D-amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Exposure to nicotine and sensitization of nicotine-induced behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Evidence of cross-tolerance between behavioural effects of nicotine and cocaine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Chronic nicotine differentially alters cocaine-induced locomotor activity in adolescent vs. adult male and female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Effect of bupropion on nicotine self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Investigating the actions of bupropion on dependence-related effects of nicotine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Neurobiological mechanisms by which nicotine mediates different types of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Mesolimbic dopaminergic pathways in fear conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Bupropion for the treatment of methamphetamine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.04.0012

21 January 2018

Identifiers

DOI

10.1211/JPP.61.04.0012

1 reference

19 December 2017

1 reference

19 December 2017